Author Contributions JWT, CET, DB, BW, SEK, SLS, NL, ARS, ET, SKM, and BJD contributed equally to this
work. JWT, CET, SKM, AA, and BJD provided project oversight for experimental design,
data management, data analysis and Interpretation, methods development, and development
of Vizome platform; BW assisted in the development of Vizome platform, project oversight
for experimental design, workflow development, data processing, management, analysis
and dissemination, and methods development; ET provided patient sample acquisition,
clinical data structure, collection, and analysis; SS, AR-S, MA, IE, AR assisted in
patient sample processing, ex vivo drug screening, DNA/RNA extractions and sequencing
sample submissions; NL, R, JD, CV provided curation and entry of patient clinical
annotations; SK provided variant confirmation, and data analysis; DB assisted in workflow
development for pre-processing and analysis of RNA-seq, Exome-Seq and Ex Vivo Drug
Screening, RNA-seq, clinical data curation and integration, methods development, multivariate
modeling and Integration, and development of Vizome platform; JR, RS, AY provided
clinical data integration from OHSU Research Data Warehouse; TK assisted in recruiting
patients and harvesting samples for analysis; CRC, RTS were co-Investigators for the
repository protocol, edited and provided feedback on manuscript; CTJ, DAP collected
samples for repository protocol, provided feedback on manuscript; MEM, RRP consented
patients and collected samples for the repository protocol and aided with clinical
annotation; DN assisted in the creation of drug screening replicate plates; CAE, KW-S,
HZ assisted in data analysis; DKE provided data analysis, data curation, and development
of analytical processes; AK, TM assisted in the development of the ex vivo drug screening
processing workflow; SJW enabled, facilitated and mentored basic, translational and
clinical research activities arising from data generated by Beat AML at the University
of Kansas Cancer Center site, participated in the Beat AML Symposia to share research
and create new research projects; ES, AC, RH, CL, RS provided exome and RNA-Seq library
creation, sequencing, and data processing; DD, CN, JP assisted in genomic isolation,
curation of samples and entry of patient clinical annotations; DLW served as a Liaison
for sample acquisition; MWD served as a Local Principal Investigator for repository
protocol, consented patients and collected samples for repository protocol, aided
with clinical annotation, edited and provided feedback on manuscript; RLW served as
a manager for their repository protocol, consented patients and collected samples
for the repository, aided with clinical annotation, edited and provided feedback on
manuscript; MML assisted in patient sample acquisition, IRB protocol development and
maintenance, clinical data structure, collection, and analysis; UM, BHC, RC, AD, K-HD,
JL, SEP assisted in patient sample acquisition; JB, RB, CC, MD, JG, HH, AJ, KJ, RJ,
SL, SL, JMac, JMar, RS, TS, AT, JWa, JWo provided patient sample processing and ex
vivo drug screening; CSH served as Principal Investigator for their local protocol;
consented patients and collected samples for repository protocol, aided with clinical
annotation, edited and provided feedback on manuscript; JMW served as Principal Investigator
for their local repository protocol, edited and provided feedback on manuscript; BCM
served as Principal Investigator for their local repository protocol, consented patients
and collected samples for repository protocol, aided with clinical annotation, edited
and provided feedback on manuscript; DCC, TLL, RHC served as Principal Investigators
for their local repository protocol, consented patients and collected samples for
repository protocol, aided with clinical annotation, edited and provided feedback
on manuscript; TM provided regulatory oversight; BJ, KW provided regulatory oversight,
curation and entry of patient clinical annotations; AB provided targetome overlay;
JC, CO assisted in tech transfer, and project development.
